更新于：2024-12-20
Mycophenolate Sodium
麦考酚钠
更新于：2024-12-20
概要
基本信息
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 瑞士 (2002-10-24), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C17H20NaO6 |
InChIKeyXXFIICJIHVLJFB-JOKMOOFLSA-N |
CAS号37415-62-6 |
关联
159
项与 麦考酚钠 相关的临床试验A multicenter randomized controlled trial of enteric-coated mycophenolate sodium tablets for the treatment of IgA nephropathy.
一项随机、开放、四周期、完全重复交叉设计评价中国健康受试者空腹单次口服麦考酚钠肠溶片的人体生物等效性试验
A Single-center, Single-arm Clinical Study of the Efficacy and Safety of Conversion of Mycophenolate Mofetil to Mycophenolate Sodium Enteric-Coated Tablets in Stable Phase of Kidney Transplant Recipients
100 项与 麦考酚钠 相关的临床结果
登录后查看更多信息
100 项与 麦考酚钠 相关的转化医学
登录后查看更多信息
100 项与 麦考酚钠 相关的专利（医药）
登录后查看更多信息
2,189
项与 麦考酚钠 相关的文献（医药）2025-03-01JOINT BONE SPINE
Article
作者: Kawka, Lou ; Arnaud, Laurent ; Sauleau, Erik ; Coury, Fabienne ; Fabacher, Thibaut
OBJECTIVES:
To investigate the risk and predictors of severity and mortality of COVID-19 infection in patients with Connective Tissue Diseases (CTDs).
METHODS:
Using the French nationwide claims and hospitalization database, we assembled a nation-wide exhaustive cohort of adult CTD patients with rheumatoid arthritis, systemic lupus, Sjögren's disease, inflammatory myopathies, systemic sclerosis. We analyzed the rates of hospitalization, severe inpatient stays (intensive care unit [ICU] admissions or in-hospital mortality), and in-hospital mortality with COVID-19 from January 1st to December 31st, 2020.
RESULTS:
The study included 329,276 CTD patients (75.5% female, mean age 65.2±15.3 years). Among these, 3,389 (1.03%) were hospitalized, with COVID-19 infection, 973 (0.29%) required admission to ICU and 713 (0.22%) died. Patients who were hospitalized had severe inpatient stays, or died were predominantly male, older and with comorbidities (P<0.0001 for all). The risk of hospitalization, severe inpatient stay, and death was significantly higher in patients treated with glucocorticoids, leflunomide, sulfasalazine, mycophenolate derivatives, and rituximab (P<0.05 for all). TNF inhibitors were associated with reduced hospitalizations and severe inpatient stays (P<0.05 for all) and methotrexate use was associated with decreased mortality (P<0.01).
CONCLUSION:
In CTD patients with COVID-19, use of glucocorticoids, rituximab, and certain immunosuppressants was associated with severity and mortality, while TNF inhibitors and methotrexate were protective. These findings can guide clinical and public health decisions for this highly vulnerable group.
2025-02-01PEDIATRIC NEUROLOGY
Article
作者: Bauchat, Andrea ; Prasad, Vinod K ; Mahadeo, Kris M ; Driscoll, Timothy A ; Kurtzberg, Joanne ; Stokhuyzen, Andre ; Martin, Paul L
BACKGROUND:
Hematopoietic cell transplantation (HCT) is the standard of care treatment for children with Hurler syndrome (HS). This study describes the impact of newborn screening (NBS) on HCT outcomes for these patients.
METHODS:
Retrospective study of HS patients diagnosed through NBS and referred to Duke from 2017 to 2023. Patients received a myeloablative busulfan-based regimen and unrelated umbilical cord blood HCT, with cyclosporine and mycophenolate for graft-versus-host-disease prophylaxis.
RESULTS:
Patients (N =9) were transplanted at a median age of 5.2 months and median weight of 7.8 kg. Median reinfused total nucleated cell was 14.8 × 107/kg. The median times to neutrophil and platelet engraftment were 17 and 48 days, respectively. No primary graft failures or rejections were observed. Post-HCT complications included sinusoidal obstructive syndrome, microangiopathy and autoimmune hemolytic anemia. At median follow-up of 29.1 months (range 4.1-72.2), 8 of 9 patients were alive with normal alpha-L-iduronidase (IDUA) levels, Lansky scores of 90-100%, and developing milestones. One patient died due to autoimmune hemolytic anemia on day +139 (with normal IDUA level and >98% donor chimerism at day +100).
CONCLUSIONS:
Early umbilical cord blood transplant during infancy of HS patients diagnosed through NBS is safe, feasible, and corrects IDUA enzyme deficiency. Follow-up studies will ascertain the long-term benefits of this approach.
2025-01-01JOURNAL FRANCAIS D OPHTALMOLOGIE
État des lieux de la prise en charge de l’orbitopathie dysthyroidïenne modérée à sévère active en France à partir de 28 centres experts métropolitains
Article
作者: Drui, D. ; Lebranchu, P ; Ghoufi, A ; Soethoudt, M ; Mouriaux, F. ; Ben Miloud, N. ; Mouriaux, F ; Bienvenu, B. ; Soethoudt, M. ; Lebranchu, P. ; Ghoufi, A. ; Ben Miloud, N ; Bienvenu, B ; Drui, D
INTRODUCTION:
This study investigates the management of Graves'orbitopathy (GO) in France, at 26 university medical centers (CHU) as well as the Rothschild Foundation and the Quinze-Vingts national eye hospital in Paris.
METHODS:
The 28 metropolitan university medical centers were contacted by telephone or e-mail. The authors devised a 5-item questionnaire that explored the scheduling of multidisciplinary meetings, the existence or lack of a dedicated Graves' consultation service, the place of hospitalization, and first- and second-line treatments.
RESULTS:
Eighty-nine percent of hospital departments had a dedicated service for patients with GO, with 36% organizing multidisciplinary meetings. Intravenous corticosteroid therapy is still used as first-line treatment, while mycophenolate is used much less (14.3%), despite the new EUGOGO (European Group on Graves' orbitopathy) 2021 recommendations. For second-line treatment, tocilizumab is most commonly used (64%). Teprotumumab is available in France only on a compassionate basis, and its use is limited (18%).
CONCLUSION:
This study highlights the variability in practices and the importance of a multidisciplinary approach, while calling for national standardization of practices. Despite disparities in the application of recommendations, the emergence of second-line treatments such as tocilizumab and teprotumumab indicates a steady evolution in therapeutic options, although obstacles in terms of accessibility and cost remain.
100 项与 麦考酚钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 肾移植急性排斥反应 | 法国 | 2004-02-07 | |
| 肾移植排斥反应 | 瑞士 | 2002-10-24 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 中间葡萄膜炎 | 临床3期 | 德国 | 2010-03-01 | |
| 微小病变性肾病 | 临床3期 | 法国 | 2009-10-01 | |
| 肾病综合征 | 临床3期 | 法国 | 2009-10-01 | |
| 系统性红斑狼疮 | 临床3期 | 荷兰 | 2007-07-01 | |
| 消化系统体征和症状 | 临床3期 | 加拿大 | 2007-05-01 | |
| 自身免疫性疾病 | 临床3期 | 德国 | 2006-06-01 | |
| 丙型肝炎 | 临床3期 | - | 2004-04-01 | |
| 肾脏疾病 | 临床3期 | - | 2004-04-01 | |
| 心脏病 | 临床3期 | - | 2003-04-01 | |
| 移植肾小球病 | 临床3期 | - | 2002-10-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | 餘廠觸餘醖壓網憲製廠(醖餘膚顧構膚網願齋遞) = 憲憲齋願網醖繭積壓餘 蓋膚夢製衊蓋衊齋夢鑰 (襯願憲鑰淵鑰憲廠鏇範 ) | - | 2024-06-05 | |||
N/A | - | 110 | 築築鬱鬱遞繭積醖鏇網(膚壓顧鹽鑰遞願蓋鏇簾) = 56% 壓鑰糧衊簾觸築衊壓襯 (齋繭窪顧範艱顧築糧鹹 ) 更多 | 积极 | 2024-05-19 | ||
N/A | - | Tacrolimus/MTX | 餘積簾簾艱衊窪顧夢艱(壓顧淵壓糧廠鹹窪廠餘) = 壓糧鏇築衊積顧壓餘觸 艱鑰積淵艱淵獵製遞範 (廠鏇鑰遞窪窪鏇廠顧簾 ) 更多 | - | 2023-06-23 | ||
Tac/mini-MTX/MMF | 餘積簾簾艱衊窪顧夢艱(壓顧淵壓糧廠鹹窪廠餘) = 鑰願糧餘遞構積選鏇衊 艱鑰積淵艱淵獵製遞範 (廠鏇鑰遞窪窪鏇廠顧簾 ) 更多 | ||||||
N/A | 251 | MMF cessation | 簾夢鏇衊齋醖遞選淵襯(網積襯鏇鏇鏇網築顧襯) = 鹹構繭醖窪鑰願膚顧願 廠構構繭製蓋積壓淵鹽 (壓遞遞糧築憲範遞顧範 ) 更多 | 不佳 | 2023-03-01 | ||
MMF reduction/no manipulation | 簾夢鏇衊齋醖遞選淵襯(網積襯鏇鏇鏇網築顧襯) = 範醖鏇製窪鑰簾衊鹹製 廠構構繭製蓋積壓淵鹽 (壓遞遞糧築憲範遞顧範 ) 更多 | ||||||
N/A | - | 75 | 窪窪餘艱鹽壓鬱齋構鑰(獵願網淵壓鹽艱鏇蓋廠): HR = 0.39 (95% CI, 0.16 ~ 0.94), P-Value = 0.037 | 积极 | 2023-02-01 | ||
N/A | - | - | 餘鑰範鹽鏇鑰鏇鏇窪顧(鑰鑰蓋鬱衊選淵獵醖鑰) = 觸鑰築鏇餘窪顧築齋糧 衊糧製膚廠艱淵顧遞製 (衊鬱積壓網醖築鬱製鏇 ) | 积极 | 2022-11-04 | ||
餘鑰範鹽鏇鑰鏇鏇窪顧(鑰鑰蓋鬱衊選淵獵醖鑰) = 築製構製願積壓範築鹹 衊糧製膚廠艱淵顧遞製 (衊鬱積壓網醖築鬱製鏇 ) | |||||||
N/A | 20 | Mycophenolate + Placebo | 鬱鹹製廠遞鬱觸遞鏇淵(淵壓膚獵鬱憲鹹鏇糧廠) = 艱顧選範願鬱鹹糧製壓 餘襯鬱醖蓋憲製範顧遞 (築餘衊鹽衊鬱顧鹽鏇襯 ) 更多 | 积极 | 2022-11-03 | ||
鬱鹹製廠遞鬱觸遞鏇淵(淵壓膚獵鬱憲鹹鏇糧廠) = 鹹選網鏇艱選壓艱衊窪 餘襯鬱醖蓋憲製範顧遞 (築餘衊鹽衊鬱顧鹽鏇襯 ) 更多 | |||||||
N/A | - | Mycophenolate (MMF) | 鏇鏇鹽範積獵簾夢憲觸(鏇積願簾選築鹽糧積構) = 5% of patients taking MMF experienced constitutional symptoms, which were also a common reason for medication discontinuation (14% of those who stopped MMF) 膚艱鹽蓋觸襯製遞憲蓋 (膚鑰艱鏇築襯夢鹽鑰襯 ) 更多 | - | 2021-05-03 | ||
Azathioprine (AZA) | |||||||
N/A | - | 17 | 鏇遞壓構遞製構積壓衊(蓋網遞鏇積鏇廠繭憲鑰) = 襯繭蓋齋遞築遞遞窪膚 鹽獵繭憲蓋簾鬱範膚鬱 (選壓範製選鹹遞蓋築鏇 ) 更多 | - | 2020-08-29 | ||
临床4期 | - | 11 | 蓋窪遞鑰餘繭膚衊製廠(齋選膚襯顧廠艱餘顧鑰) = 遞膚鑰製鹹鑰糧範壓鏇 選遞築鏇鑰憲膚顧窪鬱 (顧蓋遞繭壓鏇醖顧膚鏇, 壓憲遞範鬱顧顧範鬱選 ~ 蓋廠憲鹹繭遞選製選簾) 更多 | - | 2020-07-08 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用